December 2026 biotech catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

268 verified catalyst event(s) dated in December 2026, each linked to its official source. Verified as of 2026-09-20.

Date	Event	Company	Drug	Official source & verification
2026-12 (month) in 2mo ESTIMATED	READOUT Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Ly Phase 2 · Diffuse Large B-cell Lymphoma	KPTI Karyopharm Therapeutics Inc.	Selinexor, Selinexor, Selinexor	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers Phase 1/2 · Colorectal Cancer, Pancreatic Cancer	Lumicell, Inc.	LUM015, LUM 2.6 Imaging Device	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer Phase 1/2 · Cancer, Neoplasms	Cancer Vaccines Limited	ACIT-1	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bow Phase 2 · Irritable Bowel Syndrome	ABBV AbbVie Inc.	Eluxadoline	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patie Phase 2 · Cushing Syndrome	CORT CORCEPT THERAPEUTICS INC	relacorilant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects Wi Phase 3 · PAH, Pulmonary Hypertension	UTHR UNITED THERAPEUTICS Corp	Ralinepag	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-01 in 2mo ESTIMATED	READOUT A Study of Apalutamide in Participants With High-Risk, Localized or Locally Adva Phase 3 · Prostatic Neoplasms	Janssen Research & Development, LL	Apalutamide, Androgen Deprivation Therap	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stab Phase 3 · Chronic Stable Angina Pectoris	Tasly Pharmaceuticals, Inc.	T89 capsule	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Mus Phase 2 · Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG	TLTFF THERALASE TECHNOLOGIES INC /	Ruvidar® (TLD-1433) bladder infusion and	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD) Phase 2 · Lumbar Disc Disease	BRTX BioRestorative Therapies, In	BRTX-100, Saline	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer Phase 1/2 · Metastatic Breast Cancer	Phoenix Molecular Designs	PMD-026, fulvestrant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease ( Phase 2 · Stargardt Disease, Stargardt Macular Degeneration	Alkeus Pharmaceuticals, Inc.	ALK-001	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Exten Phase 4 · Ulcerative Colitis	BHC Bausch Health Companies Inc.	Low Dose Budesonide, High Dose Budesonid	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Phase 2/3 · Relapsed/Refractory Diffuse Large B-cell Lymphoma	KPTI Karyopharm Therapeutics Inc.	Selinexor (combination therapy), Selinex	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-01 in 2mo ESTIMATED	READOUT A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumor Phase 2 · Solid Tumor	Intra-IMMUSG Pte Ltd	PRL3-zumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors Phase 1/2 · Glioblastoma, Melanoma Stage IV	Sapience Therapeutics	ST101, Temozolomide, Radiation	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-01 in 2mo ESTIMATED	READOUT Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation Phase 1/2 · Dry Age-related Macular Degeneration	Luxa Biotechnology, LLC	RPESC-RPE-4W	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-01 in 2mo ESTIMATED	READOUT A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors Phase 2 · Solid Tumor, Adult, Cancer	EpicentRx, Inc.	AdAPT-001, Checkpoint Inhibitor, Immune	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administere Phase 2/3 · AMD, nAMD	ABBV AbbVie Inc.	ABBV-RGX-314, ABBV-RGX-314, Ranibizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) Phase 2 · HER2 Positive Metastatic Breast Cancer	Ambrx, Inc.	ARX788	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-01 in 2mo ESTIMATED	READOUT Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergo Phase 3 · Congenital Antithrombin Deficiency	Octapharma	Atenativ	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Ped Phase 3 · Primary Immunodeficiency Disease	Kedrion S.p.A.	Kedrion IVIG 10%	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castrat Phase 2 · Metastatic Castration-Resistant Prostate Cancer	Zenith Epigenetics	ZEN003694, Enzalutamide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Phase 2/3 · Acute Stroke, Ischemic Stroke	DMAC DiaMedica Therapeutics Inc.	Recombinant human tissue kallikrein	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-01 in 2mo ESTIMATED	READOUT A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Se Phase 2 · High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	K-Group, Beta, Inc., a wholly owne	azenosertib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Cap Phase 2 · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)	Sunshine Lake Pharma Co., Ltd.	HEC585 dose A, HEC585 dose B	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractor Phase 1/2 · Refractory Metastatic Colorectal Cancer, Solid Tumor	Rottapharm Biotech	CR6086, AGEN2034	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyna Phase 1/2 · Frontotemporal Dementia	DNLI Denali Therapeutics Inc.	DNL593	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Effect of Ensifentrine on Sputum Markers of Inflammation in COPD Phase 2 · COPD	Verona Pharma, Inc., a subsidiary	Ensifentrine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Phy Phase 3 · Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer	GNLX GENELUX Corp	olvimulogene nanivacirepvec, Platinum ch	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Safety and Efficacy of APG-157 in Head and Neck Cancer Phase 2 · Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity	Aveta Biomics, Inc.	APG-157	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due t Phase 1/2 · Breast Neoplasms, Brain Neoplasms	Stemline Therapeutics, Inc.	Elacestrant, Abemaciclib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Proph Phase 3 · Hereditary Angioedema	IONS IONIS PHARMACEUTICALS INC	Donidalorsen	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (i Phase 2 · Multiple Myeloma	Kite, A Gilead Company	anitocabtagene-autoleucel	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type Phase 3 · Agitation, Alzheimer's Type Dementia	Suven Life Sciences Limited	Masupirdine 50 mg, Masupirdine 100 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT Phase 3 · Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT)	Vantive Health LLC	Prismocitrate 18, PrisMax System Version	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K A Phase 1/2 · HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer	SynDevRx, Inc.	Evexomostat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Phase 2 · Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung	LTRN Lantern Pharma Inc.	LP-300, Pemetrexed, Carboplatin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refra Phase 1/2 · Lymphoma, B-Cell, Lymphoma, T-Cell	Step Pharma, SAS	STP938	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP Phase 1/2 · Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC)	AP Biosciences Inc.	AP203, AP203	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotox Phase 1/2 · LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma	Dren Bio	DR-01	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated Phase 3 · GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor	RayzeBio, Inc.	RYZ101, Everolimus, Sunitinib, Octreotid	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Pat Phase 3 · NASH, Cirrhosis, Liver	MDGL MADRIGAL PHARMACEUTICALS, IN	Resmetirom	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Ne Phase 2/3 · Glioblastoma Multiforme of Brain	TVAX Biomedical	TVI-Brain-1, Radiotherapy, Temozolomide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study of AMDX-2011P in Participants With CAA Phase 2 · Cerebral Amyloid Angiopathy	Amydis Inc.	AMDX-2011P	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fus Phase 2 · Advanced Cholangiocarcinoma, FGFR2 Fusions	Taiho Oncology, Inc.	TAS-120	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in P Phase 1/2 · Solid Tumor, Adult, Solid Tumor	A2 Biotherapeutics Inc.	A2B530, xT-Onco with HLA-LOH Assay	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes Phase 2 · Type 1 Diabetes Mellitus With Hypoglycemia	Zucara Therapeutics Inc.	ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Ob Phase 3 · Fecal Incontinence	Cook MyoSite	Iltamiocel	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Phase 2 · Hypoxic-Ischemic Encephalopathy	ReAlta Life Sciences, Inc.	RLS-0071	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Ad Phase 1/2 · Solid Tumor, Biliary Tract Cancer	TiumBio Co., Ltd.	TU2218 + KEYTRUDA® (Pembrolizumab)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Phase 2 · Lymphatic Malformation	TARA Protara Therapeutics, Inc.	TARA-002	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T- Phase 1/2 · Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma	BEAM Beam Therapeutics Inc.	BEAM-201	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study of ALTO-300 in MDD Phase 2 · Major Depressive Disorder	ANRO Alto Neuroscience, Inc.	ALTO-300	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchym Phase 1/2 · Heart Failure, Systolic	BCDA BioCardia, Inc.	CardiALLO™ Human Allogenic Culture-expan	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-a Phase 3 · Cholangiocarcinoma	TransThera Sciences (Nanjing), Inc	Tinengotinib 8 mg, Tinengotinib 10 mg, P	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced o Phase 2 · Endometrial Cancer, Endometrioid Tumor	Aadi Bioscience, Inc.	nab-sirolimus	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV Phase 2 · Mitochondrial Diseases, Pearson Syndrome	Minovia Therapeutics Ltd.	MNV-201	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-01 in 2mo ESTIMATED	READOUT Descartes-08 for Patients With Systemic Lupus Erythematosus Phase 2 · Systemic Lupus Erythematosus (SLE)	RNAC Cartesian Therapeutics, Inc.	Descartes-08	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophi Phase 2 · Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome	NS Pharma, Inc.	NS-229	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study of BN104 in the Treatment of Acute Leukemia Phase 1/2 · ALL, Adult, AML, Adult	Institut de Recherches Internation	BN104 monotherapy, BN104 monotherapy, BN	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squ Phase 2 · Vulvar Diseases, HPV Infection	Frantz Viral Therapeutics, LLC	Artesunate ointment	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Part Phase 2 · Acute Pancreatitis	Panafina, Inc.	RABI-767	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis Phase 1/2 · Light Chain (AL) Amyloidosis	Nexcella Inc.	NXC-201 CAR-T	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study to Assess Adverse Events and Change in Disease Activity in Previously Trea Phase 2 · Unresectable Metastatic Colorectal Cancer	ABBV AbbVie Inc.	ABBV-400, Bevacizumab, Folinic Acid, Flu	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Gene Therapy for ACM Due to a PKP2 Pathogenic Variant Phase 1/2 · Arrhythmogenic Cardiomyopathy, PKP2-ACM	LXEO Lexeo Therapeutics, Inc.	LX2020	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Phase 2/3 · Focal Epilepsy	BHVN Biohaven Ltd.	BHV-7000, BHV-7000, BHV-7000	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease Phase 1/2 · Moderate Alzheimer Disease	NKGen Biotech, Inc.	SNK01	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamic Phase 1/2 · Solid Tumor	Alyssum Therapeutics	AT-1965 Liposome Injection	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patie Phase 2 · NSCLC	EIKN Eikon Therapeutics, Inc.	EIK1001, Pembrolizumab, Paclitaxel, Peme	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate C Phase 1/2 · MRI Scan	Songqi Gao	MT218 injection	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT ZILRETTA in Subjects With Shoulder Osteoarthritis Phase 3 · Glenohumeral Osteoarthritis	PCRX Pacira BioSciences, Inc.	ZILRETTA	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EX Phase 3 · Pulmonary Arterial Hypertension	Gossamer Bio USA, Inc.	Seralutinib, Gereic Dry Powder Inhaler	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumo Phase 1/2 · Advanced Solid Tumor	Latticon Antibody Therapeutics, In	LAT010, LAT010 + ICI	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-01 in 2mo ESTIMATED	READOUT A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) Phase 2 · Pressure Ulcer, Stage IV, Osteomyelitis	Biocomposites Ltd	STIMULAN VG	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal He Phase 2 · Paroxysmal Nocturnal Hemoglobinuria	OMER OMEROS CORP	OMS906 study drug	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Phase 2 Study of WGI-0301 for Advanced HCC Phase 2 · Advanced Hepatocellular Carcinoma (HCC)	Zhejiang Haichang Biotech Co., Ltd	WGI-0301 at MTD/RP2D dose IV infusion, Q	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT SPI-1005 in Adults Receiving Cochlear Implant Phase 2 · Hearing Loss, Cochlear Trauma	Sound Pharmaceuticals, Incorporate	Ebselen	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalize Phase 2 · Steroid Refractory GVHD	ReAlta Life Sciences, Inc.	RLS-0071	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients W Phase 3 · Acute Hereditary Angio Edema	Octapharma	OCTA-C1-INH	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies Phase 1/2 · Advanced or Metastatic Solid Tumors, Breast Cancer	858 Therapeutics, Inc.	ETX-19477	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With o Phase 2 · Acute Ischemic Stroke	NoNO Inc.	NoNO-42	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Phase 3 · Binge-Eating Disorder	AXSM Axsome Therapeutics, Inc.	Solriamfetol 150 mg, Solriamfetol 300 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Phase 2 · Myasthenia Gravis, Myasthenia Gravis, MuSK	NMD Pharma A/S	NMD670	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) Phase 2 · Basal Cell Carcinoma	Highlight Therapeutics	BO-112	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors Phase 1/2 · Melanoma Stage IV, Solid Tumor	Georgiamune Inc	GIM-531, Anti-PD-1 monoclonal antibody	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-01 in 2mo ESTIMATED	READOUT A Study of RSLV-132 in Females With Sjögren's Disease Phase 2 · Primary Sjögren Syndrome	Resolve Therapeutics	RSLV-132	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Long-term Safety and Tolerability of BHV-7000 Phase 2 · Focal Epilepsy	BHVN Biohaven Ltd.	BHV-7000, BHV-7000	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Phase 2 · Moderately to Severely Active Crohn Disease	ABVX Abivax S.A.	Obefazimod	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adoles Phase 3 · Hidradenitis Suppurativa	ABBV AbbVie Inc.	Lutikizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Phase 1/2 Trial of ADI-270 in ccRCC Phase 1/2 · Clear Cell Renal Cell Carcinoma	ACET Adicet Bio, Inc.	ADI-270, Fludarabine, Cyclophosphamide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BR Phase 2 · For Treatment of Chronic Hepatitis B Virus Infection	Brii Biosciences Limited	BRII-179, BRII-835 (VIR-2218), PEG-IFNα	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy Phase 2 · Multifocal Motor Neuropathy	DNTH Dianthus Therapeutics, Inc.	Claseprubart	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shif Phase 3 · Excessive Sleepiness, Shift-work Disorder	AXSM Axsome Therapeutics, Inc.	Solriamfetol 150 mg, Solriamfetol 300 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Double Blind Study Performed to Evaluate the Efficacy and the Safety of Eschar Phase 3 · Venous Leg Ulcer (VLU)	MDWD MediWound Ltd.	EscharEx (EX-03)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone Mas Phase 2 · Postmenopausal Osteoporosis	Angitia Biopharmaceuticals	AGA2118	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Phase 1/2 · Solid Tumor	Lamassu Bio Inc	SA53-OS (phase 1), SA53-OS (phase 2)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control Phase 2 · Myopia, Progressive	Sunhawk Vision Biotech, Inc.	SHJ002, Atropine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Phase 3 · Eosinophilic Esophagitis	Dr. Falk Pharma GmbH	Budesonide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given D Phase 2 · Refractory Metastatic Colorectal Cancer	DCTH DELCATH SYSTEMS, INC.	Melphalan/HDS Followed by Consolidation	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten R Phase 1/2 · KRAS G12D Mutation	Ranok Therapeutics (Hangzhou) Co.,	RNK08954-01	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-01 in 2mo ESTIMATED	READOUT A Study to Learn More About the Effects and Safety of Felzartamab Infusions in A Phase 3 · Antibody-mediated Rejection	BIIB BIOGEN INC.	Felzartamab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Tissue Repair Gel in Venous Leg Ulcers in AU/US Phase 3 · Venous Leg Ulcer, Venous Ulcer	TR Therapeutics	TR987 0.1% gel + Standard of Care	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Phase 2/3 · Microvillus Inclusion Disease, Congenital Disorders	Napo Pharmaceuticals, Inc.	Crofelemer Powder for Oral Solution	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia Phase 2 · Narcolepsy Type 1, Narcolepsy Type 2	Centessa Pharmaceuticals (UK) Limi	ORX750	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Wit Phase 1/2 · Type 1 Diabetes Mellitus, T1D	COUR Pharmaceutical Development Co	CNP-103	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-01 in 2mo ESTIMATED	READOUT Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Phase 3 · Pneumococcal Infections	SNY Sanofi	PCV21, 20vPCV	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-01 in 2mo ESTIMATED	READOUT Spermatogonial Differentiation Via Testicular Organoid Phase 1/2 · Infertility, Male, Gene Abnormality	CellARTs Inc.	Stem cell, Genetic Screening, Genetic Re	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study of Navenibart in Participants With Hereditary Angioedema Phase 3 · Hereditary Angioedema (HAE)	Astria Therapeutics, Inc.	navenibart	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Phase 2 · Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy	DWTX Dogwood Therapeutics, Inc.	Halneuron, Halneuron (Open Label Extensi	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Phase 1/2 · oGHVD	Regenerative Ocular Immunobiologic	d-MAPPS, PI and Patient Masked	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT SPI-1005 for the Treatment of Meniere's Disease (Open Label) Phase 3 · Meniere's Disease, Ménière's Disease	Sound Pharmaceuticals, Incorporate	Ebselen	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-01 in 2mo ESTIMATED	READOUT Study to Evaluate the Safety and the Immunogenicity of a Second Generation Struc Phase 1/2 · Pandemic Influenza Immunization, Healthy Volunteers	SNY Sanofi	Pandemic flu H5 HA mRNA SD2 vaccine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retini Phase 2 · Retinitis Pigmentosa	jCyte, Inc	human retinal progenitor cells, Mock inj	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Safety and Efficacy of VDPHL01 in Males With AGA Phase 3 · Androgenetic Alopecia, AGA	MANE Veradermics, Inc	VDPHL01	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Phase 1/2 · Neurotrophic Keratitis	KRYS Krystal Biotech, Inc.	KB801	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerabil Phase 3 · Developmental and Epileptic Encephalopathy 1	PRAX Praxis Precision Medicines,	1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermo Phase 3 · Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa	KRYS Krystal Biotech, Inc.	KB803	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Saf Phase 3 · Epileptic Encephalopathy, SCN2A Encephalopathy	PRAX Praxis Precision Medicines,	1mg elsunersen, 0.5mg elsunersen	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Sy Phase 2 · Non-obstructive Hypertrophic Cardiomyopathy	Imbria Pharmaceuticals, Inc.	Ninerafaxstat 200mg MR	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Phase 3 · Chronic Primary Immune Thrombocytopenia (ITP)	Kedrion S.p.A.	Kedrion IVIG 10%	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemoli Phase 2 · Chronic Pruritus of Unknown Origin	Galderma R&D	nemolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infect Phase 3 · Viral Hepatitis	VIR Vir Biotechnology, Inc.	Tobevibart, Elebsiran, Bulevirtide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease ( Phase 1/2 · Parkinson's Disease (PD)	EicOsis Human Health Inc.	EC5026 oral tablet	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Phase 2 · Nausea, Vomiting	LLY ELI LILLY & Co	LY3537021, Background Chemotherapy	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifung Phase 2 · Invasive Mould Infection	Elion Therapeutics, Inc.	EL219, Active Comparator- IV Antifungal	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment Phase 3 · Social Anxiety Disorder (SAD)	VNDA Vanda Pharmaceuticals Inc.	VQW-765	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis Phase 2 · Atopic Dermatitis (AD)	Enveda Therapeutics	ENV-294	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults Phase 2 · Asthma	Enveda Therapeutics	ENV-294	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD Phase 2 · Pulmonary Hypertension, Interstitial Lung Disease (ILD)	Pulmovant, Inc.	inhaled mosliciguat, Dry Powder Inhaler	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma Phase 3 · Primary Vitreoretinal Lymphoma	ALDX Aldeyra Therapeutics, Inc.	ICM ADX-2191 injection, Monthly ADX-2191	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-01 in 2mo ESTIMATED	READOUT A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1 Phase 3 · Nausea and Vomiting, Obesity	VNDA Vanda Pharmaceuticals Inc.	Tradipitant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Partici Phase 2 · RSV Infection, RSV	ENTA ENANTA PHARMACEUTICALS INC	zelicapavir	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Canc Phase 3 · Lung Cancer, Lung Metastases	Vergent Bioscience, Inc.	Abenacianine, Near Infrared (NIR) Imagin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospit Phase 2 · Hypertension, Acute Severe Hypertension	KARD Kardigan, Inc.	Tonlamarsen	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL Phase 1/2 · Bipolar I Disorder	ALZN Alzamend Neuro, Inc.	AL001, Lithium carbonate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT A Clinical Study Evaluating Licaminlimab for Dry Eye Disease Phase 2/3 · Dry Eye Disease (DED)	OCS Oculis Holding AG	Artificial Tear Run-in, licaminlimab, Ve	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12 (month) in 2mo ESTIMATED	READOUT Rademikibart IV for Acute Asthma and COPD Exacerbation Phase 2 · Asthma Acute, COPD Exacerbation Acute	Connect Biopharm LLC	Rademikibart	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-02 in 2mo ESTIMATED	READOUT A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Ca Phase 3 · Metastatic Castration-Resistant Prostate Cancer	PFE PFIZER INC	PF-06821497, Enzalutamide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-02 in 2mo ESTIMATED	READOUT A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 t Phase 3 · Severe Alopecia Areata	PFE PFIZER INC	Ritlecitinib higher dose, Ritlecitinib l	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-03 in 2mo ESTIMATED	READOUT A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Phase 2 · Non-Transfusion Dependent Beta-Thalassemia (NTDT)	REGN REGENERON PHARMACEUTICALS, I	REGN7999	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-03 in 2mo ESTIMATED	READOUT A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Phase 2 · Alzheimer's Disease	Eisai Inc.	E2814, Lecanemab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-04 in 3mo ESTIMATED	READOUT A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth D Phase 3 · Lyme Disease	PFE PFIZER INC	VLA15	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-08 in 3mo ESTIMATED	READOUT A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation Phase 3 · Atrial Fibrillation	Janssen Research & Development, LL	Milvexian, Apixaban, Apixaban Placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-08 in 3mo ESTIMATED	READOUT A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults Phase 2 · Hidradenitis Suppurativa	PFE PFIZER INC	Ritlecitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-09 in 3mo ESTIMATED	READOUT A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis As Phase 3 · Psychosis Associated With Alzheimer's Disease	Karuna Therapeutics, Inc., a Brist	KarXT	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-10 in 3mo ESTIMATED	READOUT A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Ba Phase 2 · Chronic Kidney Disease and Hypertension	AZN ASTRAZENECA PLC	Baxdrostat/dapagliflozin, Baxdrostat/Pla	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-11 in 3mo ESTIMATED	READOUT Extended Access of Momelotinib in Adults With Myelofibrosis Phase 2 · Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF)	GlaxoSmithKline	MMB	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-11 in 3mo ESTIMATED	READOUT A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer Th Phase 2 · Urothelial Carcinoma	Seagen, a wholly owned subsidiary	disitamab vedotin, pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-14 in 3mo ESTIMATED	READOUT Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moder Phase 2 · Metastatic Castration-Resistant Prostate Cancer (mCRPC)	NVS NOVARTIS AG	AAA617, 68Ga-PSMA-11	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-14 in 3mo ESTIMATED	READOUT Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Phase 2 · Heart Failure	BMY BRISTOL MYERS SQUIBB CO	BMS-986435	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-14 in 3mo ESTIMATED	READOUT Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) Phase 3 · Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)	AMGN AMGEN INC	ABP 234, Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-14 in 3mo ESTIMATED	READOUT A Study on the Immune Response and Safety of the Second Dose of an Investigation Phase 3 · Chickenpox	GlaxoSmithKline	Investigational varicella vaccine, Marke	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-14 in 3mo ESTIMATED	READOUT A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 Phase 2 · Palmoplantar Pustulosis	LEO Pharma	Delgocitinib cream, Vehicle cream	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-14 in 3mo ESTIMATED	READOUT A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help P Phase 2 · Overweight, Obesity	NVO NOVO NORDISK A S	NNC0662-0419	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-15 in 3mo ESTIMATED	READOUT Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants ( Phase 3 · Schizophrenia	Gedeon Richter Plc.	Cariprazine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-15 in 3mo ESTIMATED	READOUT The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP5 Phase 1/2 · Advanced Solid Tumor, Advanced Malignant Neoplasm	PMVP PMV Pharmaceuticals, Inc.	rezatapopt, pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-15 in 3mo ESTIMATED	READOUT A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab Phase 1/2 · Solid Tumor, Adult, Refractory Cancer	GV20 Therapeutics	GV20-0251, GV20-0251, GV20-0251 and Pemb	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-15 in 3mo ESTIMATED	READOUT Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Phase 3 · Non-Clear Cell Renal Cell Carcinoma	EXEL EXELIXIS, INC.	XL092, Nivolumab, Sunitinib Malate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-15 in 3mo ESTIMATED	READOUT PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With ACh Phase 3 · Generalized Myasthenia Gravis, gMG	Alexion Pharmaceuticals, Inc.	Gefurulimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-15 in 3mo ESTIMATED	READOUT Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Ad Phase 2 · Locally Advanced Pancreatic Adenocarcinoma	EXACT Therapeutics AS	Acoustic Cluster Therapy, Modified FOLFI	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-15 in 3mo ESTIMATED	READOUT A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Modera Phase 3 · Moderate to Severe Glabellar Lines	Ipsen	Corabotase	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-15 in 3mo ESTIMATED	READOUT A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults W Phase 3 · Moderate to Severe Glabellar Lines	Ipsen	Corabotase	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-16 in 3mo ESTIMATED	READOUT A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodyn Phase 3 · NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis	Hoffmann-La Roche	Satralizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-16 in 3mo ESTIMATED	READOUT A Clinical Investigation of a Topical Moisturizer on Skin Barrier Function in Ad Phase 4 · Sensitive Skin	Good Molecules, LLC	White petrolatum, Investigational moistu	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-17 in 3mo ESTIMATED	READOUT A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Phase 2 · Crohn's Disease	SNY Sanofi	SAR442970	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-17 in 3mo ESTIMATED	READOUT A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participant Phase 2 · Ulcerative Colitis	SNY Sanofi	SAR442970	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-18 in 3mo ESTIMATED	READOUT Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymo Phase 2/3 · Breast Cancer	Han Xu, M.D., Ph.D., FAPCR, Sponso	Raloxifene - Usual, Raloxifene - Study	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-18 in 3mo ESTIMATED	READOUT A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo i Phase 2 · Migraine	ABBV AbbVie Inc.	MEDI0618	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-21 in 3mo ESTIMATED	READOUT A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Phase 3 · Hidradenitis Suppurativa	UCB Biopharma SRL	Bimekizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-22 in 3mo ESTIMATED	READOUT A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease Phase 2 · Alzheimer Disease	Janssen Pharmaceutica N.V., Belgiu	JNJ-64042056	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-22 in 3mo ESTIMATED	READOUT Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants Phase 3 · Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD	Adverum Biotechnologies, Inc.	Ixo-vec, Aflibercept	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-23 in 3mo ESTIMATED	READOUT A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients Phase 2 · Prostatic Neoplasm	NVS NOVARTIS AG	AAA617, AAA517, Piflufolastat F 18, ARPI	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-23 in 3mo ESTIMATED	READOUT A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Phase 1/2 · Non-Hodgkin Lymphoma	Cho Pharma Inc.	CHO-H01, CHO-H01 at RP2D, Lenalidomide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-23 in 3mo ESTIMATED	READOUT FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration- Phase 2 · Metastatic Castration-resistant Prostate Cancer	Fusion Pharmaceuticals Inc.	FPI-2265	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-23 in 3mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzab Phase 2 · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion	SNY Sanofi	frexalimab, brivekimig, rilzabrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-25 in 3mo ESTIMATED	READOUT A Study on the Immune Response and Safety of an Investigational Chickenpox Vacci Phase 3 · Chickenpox	GlaxoSmithKline	Investigational varicella vaccine_Lot 1,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-25 in 3mo ESTIMATED	READOUT A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Phase 2 · Geographic Atrophy	Boehringer Ingelheim	BI 1584862	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-25 in 3mo ESTIMATED	READOUT A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spont Phase 2 · Chronic Spontaneous Urticaria	PFE PFIZER INC	Ritlecitinib 50 mg, Ritlecitinib 100 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-26 in 3mo ESTIMATED	READOUT Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovari Phase 3 · Carcinoma, Ovarian Epithelial, Ovarian Neoplasms	CanariaBio Inc.	Oregovomab, Paclitaxel, Carboplatin, Car	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-26 in 3mo ESTIMATED	READOUT A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Partici Phase 3 · Hidradenitis Suppurativa (HS)	INCY INCYTE CORP	Povorcitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-27 in 3mo ESTIMATED	READOUT Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Vari Phase 1/2 · Breast Cancer, Metastatic Breast Cancer	Stemline Therapeutics, Inc.	Elacestrant, Alpelisib, Everolimus, Ribo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-27 in 3mo ESTIMATED	READOUT Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients Wit Phase 2 · High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion	Amplexd Therapeutics, Inc.	EGCG and Quinine Sulfate Vaginal Supposi	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-28 in 3mo ESTIMATED	READOUT A Long-term Treatment Extension Study of Niraparib in Participants Who Completed Phase 2 · Ovarian Neoplasms, Breast Neoplasms	GlaxoSmithKline	Niraparib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-28 in 3mo ESTIMATED	READOUT Lorlatinib Continuation Study Phase 4 · Non-Small-Cell Lung Cancer, NSCLC	PFE PFIZER INC	Lorlatinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-28 in 3mo ESTIMATED	READOUT Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-a Phase 2 · Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition	Frantz Viral Therapeutics, LLC	Artesunate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-28 in 3mo ESTIMATED	READOUT A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevromet Phase 3 · Metastatic Castrate Resistant Prostate Cancer (mCRPC)	PFE PFIZER INC	PF-06821497, Docetaxel, Enzalutamide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-29 in 3mo ESTIMATED	READOUT A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult P Phase 2 · Hypercholesterolemia	REGN REGENERON PHARMACEUTICALS, I	Alirocumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients Phase 3 · Tuberous Sclerosis Complex	NVS NOVARTIS AG	everolimus	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT Combination of TATE and PD-1 Inhibitor in Liver Cancer Phase 2 · Hepatocellular Carcinoma, Gastric Cancer	Teclison Ltd.	Nivolumab Injectable Product, Trans-arte	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanc Phase 3 · Renal Cell Carcinoma	Xynomic Pharmaceuticals, Inc.	Pazopanib, Abexinostat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT BS01 in Patients With Retinitis Pigmentosa Phase 1/2 · Retinitis Pigmentosa	Bionic Sight LLC	BS01	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Pa Phase 1/2 · Hematologic Malignancies	SLS SELLAS Life Sciences Group,	SLS009, venetoclax, azacitidine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradioth Phase 3 · Urinary Bladder Neoplasms	Janssen Research & Development, LL	Cetrelimab, TAR-200, Cisplatin, Gemcitab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT NEO100 and High-Grade Meningioma Phase 2 · Residual, Progressive or Recurrent Grade II or III Meningioma	NTHI NEONC TECHNOLOGIES HOLDINGS,	NEO100	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Phase 2 · Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma	NATCO Pharma Ltd.	NRC-2694-A, Paclitaxel	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult W Phase 2 · Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary	CanariaBio Inc.	Oregovomab, Niraparib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given Phase 1/2 · Breast Cancer	PFE PFIZER INC	ARV-471, Ribociclib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherto Phase 2/3 · Netherton Syndrome	QNRX Quoin Pharmaceuticals Ltd.	QRX003, 4% Lotion	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in Phase 3 · Breast Cancer	PFE PFIZER INC	Vepdegestrant (ARV-471/PF-07850327), Pal	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT Iptacopan in Patients With ANCA Associated Vasculitis Phase 2 · Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis	NVS NOVARTIS AG	Iptacopan, Rituximab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-C Phase 2 · T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma	Allotera Therapeutics	WU-CART-007	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Ass Phase 2 · Hypoparathyroidism	Amorphical Ltd.	AMOR-1, Crystalline Calcium Carbonate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Part Phase 3 · Depressive Disorder, Major	Janssen Research & Development, LL	Seltorexant, Selective Serotonin Reuptak	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VE Phase 2 · VEXAS, VEXAS Syndrome	Swedish Orphan Biovitrum	Pacritinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Phase 3 · Myasthaenia Gravis	RNAC Cartesian Therapeutics, Inc.	Decartes-08	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK196 Phase 1/2 · Shock, Cardiogenic	4TEEN4 Pharmaceuticals GmbH	AK1967 (Invobenitug also known as Prociz	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome Phase 2/3 · Netherton Syndrome	QNRX Quoin Pharmaceuticals Ltd.	QRX003, 4% Lotion	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncy Phase 2 · Respiratory Syncytial Virus Infections	SGIOF SHIONOGI & CO LTD	S-337395	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burn Phase 2 · Burns	Skingenix, Inc.	Investigational Drug, MW-III, Silvadene®	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumor Phase 3 · Solid Tumors	Hoffmann-La Roche	Pertuzumab, Trastuzumab, Other Combinati	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an N Phase 2 · Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion	Partner Therapeutics, Inc.	zenocutuzumab (MCLA-128)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-L Phase 3 · Cancer	Hoffmann-La Roche	Atezolizumab, Bevacizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemi Phase 1/2 · Glioblastoma	INO INOVIO PHARMACEUTICALS, INC.	INO-5401, INO-9012, Cemiplimab, Radiatio	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and R Phase 3 · Fabry Disease	Amicus Therapeutics	migalastat HCl 150 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD- Phase 1/2 · Non Small Cell Lung Cancer, Advanced Solid Tumor	OncoC4, Inc.	ONC-392, Pembrolizumab, Docetaxel	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refra Phase 1/2 · Epithelial Ovarian Cancer, Gastric Adenocarcinoma	Klus Pharma Inc.	SKB264	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants Wi Phase 3 · B-cell Malignancies	ONC BeOne Medicines Ltd.	Zanubrutinib, Tislelizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT PF-07104091 as a Single Agent and in Combination Therapy Phase 2 · Small Cell Lung Cancer, Ovarian Cancer	PFE PFIZER INC	PF-07104091 monotherapy dose escalation,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of F Phase 3 · Metastatic Castration-Resistant Prostate Cancer (mCRPC)	JHPCY Jiangsu Hengrui Pharmaceutic	Fuzuloparib , Abiraterone acetate and Pr	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT DALY II USA/ MB-CART2019.1 for DLBCL Phase 2 · Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma	Miltenyi Biomedicine GmbH	zamtocabtagene autoleucel (MB-CART2019.1	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Tre Phase 1/2 · Sickle Cell Disease	Kamau Therapeutics	nula-cel Drug Product	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Phase 2 · COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm	GeoVax, Inc.	COVID-19 Vaccine, Diagnostic Laboratory	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dyst Phase 2/3 · Congenital Myotonic Dystrophy	AMO Pharma Limited	Tideglusib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome Phase 3 · Alagille Syndrome	Albireo, an Ipsen Company	Odevixibat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Ave Phase 3 · Advanced Malignancies, NSCLC	PFE PFIZER INC	Avelumab, Lorlatanib, Talazoparib, Pemet	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects A Phase 2 · Acute Ischemic Stroke	Lumosa Therapeutics Co., Ltd.	LT3001 Drug Product	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Phase 2 · Hepatocellular Carcinoma, Advanced Cancer	TaiRx, Inc.	Nivolumab Injection [Opdivo], CVM-1118	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Ad Phase 1/2 · Solid Tumor, Advanced Solid Tumor	Impact Therapeutics, Inc.	IMP9064	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With D Phase 3 · Cancer	AZN ASTRAZENECA PLC	Durvalumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium Phase 3 · Pterygium	Cloudbreak Therapeutics, LLC	CBT-001, Vehicle	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hyper Phase 2 · Diabetes Mellitus, Type 2, Hypertriglyceridemia	MNOV MEDICINOVA INC	MN-001, MN-001 placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIG Phase 2 · Urothelial Cancer	Hoffmann-La Roche	Atezolizumab, Tobemstomig, Tiragolumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmona Phase 2/3 · Pulmonary Arterial Hypertension	Insmed Incorporated	Treprostinil Palmitil	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare Phase 2/3 · Acute Gout Flare, Gout Attack	Olatec Therapeutics, Inc.	Dapansutrile	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Su Phase 3 · Lupus Erythematosus, Systemic	Viatris Innovation GmbH	Cenerimod	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects Wit Phase 3 · Leukocyte Adhesion Deficiency	AUG Therapeutics	AVTX-803	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Ac Phase 1/2 · Relapsed or Resistant Acute Leukaemias	Lin BioScience, Inc	LBS-007	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. Phase 1/2 · Advanced Solid Tumors	AskGene Pharma, Inc.	ASKG915, Paclitaxel + Bevacizumab, Fruqu	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Ph Phase 3 · Metastatic Breast Cancer	Hoffmann-La Roche	Inavolisib, Phesgo, Taxane-based Chemoth	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Di Phase 2 · Crohns Disease	Hoffmann-La Roche	Afimkibart	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Sub Phase 1/2 · Alcohol Use Disorder	CMND Clearmind Medicine Inc.	CMND-100	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizu Phase 1/2 · Glioma, Glioblastoma Multiforme	Aveta Biomics, Inc.	APG-157	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Global Trial in APG2575 for Patients With CLL/SLL Phase 3 · CLL/SLL	Ascentage Pharma Group Inc.	lisaftoclax +BTK inhibitor, BTK inhibito	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given Phase 1/2 · Breast Cancer	PFE PFIZER INC	vepdegestrant, Samuraciclib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy Phase 1/2 · Myotonic Dystrophy 1	SRPT Sarepta Therapeutics, Inc.	SRP-1003 IV Infusion, SRP-1003 SC Inject	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Bre Phase 2 · Triple Negative Breast Cancer (TNBC)	Rhizen Pharmaceuticals SA	Tenalisib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopau Phase 2 · Vulvo Vaginal Atrophy (VVA)	Azure Biotech Inc.	Lasofoxifene Tartrate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants Phase 2 · Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL	Frantz Viral Therapeutics, LLC	Artesunate ointment	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's L Phase 1/2 · B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins	Estrella Biopharma, Inc.	EB103	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Phase 3 · Myelofibrosis, Post-PV MF	Kartos Therapeutics, Inc.	Navtemadlin, Navtemadlin placebo, Ruxoli	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF) Phase 1/2 · Cystic Fibrosis	Spirovant Sciences, Inc.	SP-101 and doxorubicin Cohort 1, SP-101	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-co Phase 4 · SARS-CoV-2	ModernaTX, Inc.	mRNA-1273 Variant-containing Formulation	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults Phase 3 · Dravet Syndrome	Longboard Pharmaceuticals	LP352	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as Phase 3 · Hemorrhage	Corza Medical GmbH	TachoSil, Surgicel Original	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors Phase 2 · Breast Cancer, Gastric Cancer	JAZZ Jazz Pharmaceuticals plc	Zanidatamab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apn Phase 2 · Sleep Apnea	SGIOF SHIONOGI & CO LTD	Sivopixant, Acetazolamide, SASS-001	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer Phase 4 · Metastatic Urothelial Carcinoma	Astellas Pharma Global Development	Enfortumab Vedotin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Phase 3 · Viral Hepatitis	VIR Vir Biotechnology, Inc.	Tobevibart, Elebsiran	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Phase 2 · Chronic Inducible Urticaria, Chronic Spontaneous Urticaria	Blueprint Medicines Corporation	BLU-808	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants W Phase 3 · Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy	Clarity Pharmaceuticals Ltd	64Cu-SAR-bisPSMA	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, a Phase 2 · Parkinson Disease	Hillhurst Biopharmaceuticals, Inc.	HBI-002, Vehicle (placebo)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as AN Phase 3 · Guillain-Barre Syndrome	ANNX Annexon, Inc.	Tanruprubart	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms Phase 2 · Vasomotor Symptoms	Tioga Pharmaceuticals	Asimadoline	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients Phase 2 · Non-segmental Vitiligo	Elixiron Immunotherapeutics (Hong	EI-001	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder Phase 2 · Major Depressive Disorder (MDD)	SUPN SUPERNUS PHARMACEUTICALS, IN	SPN-821 2400 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE) Phase 2 · Ocular Rosacea	TARS Tarsus Pharmaceuticals, Inc.	lotilaner, Vehicle	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence Phase 2 · Candidiasis, Vulvovaginal	Sano Chemicals Inc	OCF001 Intravaginal Gel	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change